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Asthma is a disease with an increasing prevalence rate, 
and there is a strong interaction between airway 
epithelial cells and the immune system against the 
pathogenesis of asthma1. The most common 
immunopathology in asthma is inflammation of type 2 
characterized by processes in the airway epithelium 
involving cytokines2. Symptoms of asthma include 
wheezing, shortness of breath, heavy chest, and 
coughing at night and early morning. There is muscle 
contraction in the bronchial walls, swelling of the 
bronchial mucosa, and increased mucus production in 
the secretory cells of the bronchial mucosa, resulting in 
increased resistance to airflow through the narrowed 
bronchi. This condition occurs in shortness of breath3,4. 
The increase in the eosinophil count in asthmatic patients 
correlated with the severity of the respiratory failure and 
was predicted to increase the risk of sequential sub-
exacerbations. Immunoglobulin E (IgE) is involved early 
in the inflammatory cascade and may be considered a 
cause of allergic asthma5,6. 
Moringa oleifera Lam. is considered a miracle plant with 
many benefits for humans and is credible for providing 
good nutrition and healing and preventing many 
diseases7. The pharmacologically reported effects include 
antibacterial, antifungal, antiviral, anti-inflammatory and 
analgesic, antioxidant, hypotensive, antiulcer, 
cardioprotective anesthetic, antiurolithic, and wound 
healing activity8-12. The M. oleifera plant has various 
therapeutic properties. For example, the general 
nutritional content of M. oleifera to several specific 
properties, including anti-inflammatory, antimicrobial, 
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Asthma is a chronic inflammation of the respiratory tract. This study 
aimed to prove Moringa oleifera Lam. leaves extract's effect on reducing 
the eosinophil count and mast cells in asthmatic mice. Twenty BALB/c 
mice that met the inclusion criteria were divided into four groups of 
standard control (K1), negative control (K2), dexamethasone (K3), and 
M. oleifera leaves extract (K4). On days 0 and 7, intraperitoneal 
ovalbumin (OVA) was sensitized. On days 14, 16, and 18, mice were 
re-sensitized by inhalation using 1% OVA in sterile 0.9% NaCl. On 
days 18 to 25, K1 and K2 groups were given Na-CMC, the K3 group 
was given dexamethasone 1.3 µg/day, and the K4 group was given M. 
oleifera leaves extract 3.9 mg/day. On the 25th day, the mice were 
terminated to analyze the eosinophil count and stable bronchiolar 
mast cells. In conclusion, M. oleifera leaves extract was proven to 
decrease the eosinophil count with a p-value <0.05 and could stabilize 
bronchiolar mast cells with a p-value <0.05. 
 
Received: December 11th, 2020 
Accepted: May 22nd, 2021 
Published: August 30th, 2021 
   
 
© 2021 Dian Arsanti Palupi, Tri Wahyuni Prasetyowati, Dwi Murtiningsih, Dede Mahdiyah. Published by Institute 
for Research and Community Services Universitas Muhammadiyah Palangkaraya. This is an Open Access article 




Borneo Journal of Pharmacy, Vol 4 Issue 3, August 2021, Page 171 – 177  e-ISSN: 2621-4814 
172 
antihyperglycemic, antioxidant and anticancer 
properties13. The secondary metabolites of M. oleifera 
leaves are alkaloids, saponins, phenolics, tannins, 
flavonoids, and steroids14. Oral administration of M. 
oleifera aqueous extract has been shown to reduce 
symptoms of type I allergy in ovalbumin-induced rats. 
Aqueous extract of M. oleifera altered the T helper 
(Th)1/Th2 balance towards Th1 dominance in the allergy 
model in mice, resulting in suppression of mast cell 
activation, followed by histamine release15. 
Treatment decisions must consider the biological 
background in this case of inflammation as they tend to 
predict the patient's response to asthma treatment16. 
Agrawal and Mehta17 studied fine powder dry seeds of 3 
g on M. oleifera seeds for three weeks showing a 
significant increase in forced vital capacity, forced 
expiratory volume in one second, and peak expiratory 
flow rate values in patient subjects. Moringa oleifera leaves 
extract was proven to decrease the eosinophil count and 
could stabilize bronchiolar mast cells18. However, 
research on the anti-plasma activity of M. oleifera leaves 
extract reduces the eosinophil count, and the stability of 
the number of mast cells in asthmatic mice has not been 
reported. Therefore, this study aims to prove the effect of 
M. oleifera leaves extract on reducing eosinophils and 
mast cells in asthmatic mice. 
 
MATERIALS AND METHODS 
Materials 
The materials used in this study were M. oleifera Lam. 
leaves extract (Deltomed Laboratories, Indonesia), 
dexamethasone (Cayman Chemical, US), ovalbumin 
(OVA) (Worthington Biochemical Corporation, US), and 
alhydrogel® (InvivoGen, US). The main instruments 
used in this study were electronic nebulizer, automated 
hematology analyzer XS1000i/800i (Sysmex, Japan), and 
Olympus digital microscope OptiLab Pro 6.1. The 
software used for data analysis was IBM SPSS Statistics 
®16.0. 
Methods 
Preparation of test animals 
The test animals used were female BALB/c mice 
weighing 20-30 g, which has been acclimatized for a 
week. All test animals were given drink and standard 
feed ad libitum. Female BALB/c mice were used because 
they showed a better response to OVA than males19. 
Research design 
This study used a laboratory experimental quantitative 
approach with a post-test only control group design in 
asthmatic mice in vivo. The test group was divided into 
four groups: standard control (K1), negative control (K2), 
positive control (K3), and M. oleifera leaves extract group 
(K4). The treatment dose for M. oleifera leaves extract 
produced by Deltomed Laboratories was 1500 mg/day, 
with the conversion dose for mice was 1500 mg x 0.0026 
= 3.9 mg/day. For the standard control group, BALB/c 
mice were given sterile 0.9% NaCl by intraperitoneal 
injection on days 0 and 7. On days 14, 16, and 18, 
inhalation was carried out with sterile 0.9% NaCl as 
much as 8 mL per treatment by inhalation using an 
electronic nebulizer for 20 minutes with airflow volume 
and volume nebulization on a scale of 1 on day 1. On 
days 18, 19, 20, 21, 22, 23, and 24, mice were treated with 
0.5% Na-CMC orally 1 mL/day. For K2, K3, and K4 
groups, all BALB/c mice have sensitized with 10 µg 
OVA + 1 mg alhydrogel® suspended in 0.5 mL of 0.9% 
sterile NaCl by intraperitoneal injection on days 0 and 7. 
On days 14, 16, and 18, inhalation was carried out with 
sterile 0.9% NaCl as much as 8 mL per treatment by 
inhalation using an electronic nebulizer for 20 minutes 
with airflow volume and volume nebulization on a scale 
of 1 on day 1. On days 18, 19, 20, 21, 22, 23, and 24, mice 
were treated with 0.5% Na-CMC orally 1 mL/day (K2), 
1.3 µg dexamethasone orally 1 mL/day (K3), and 3.9 mg 
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M. oleifera leaves extract orally 1 mL/day (K4). The 
research design schematic was shown in Figure 1. 
 
Figure 1. Research design. R: Randomization; O1-O4: 
Observation of the eosinophil count and bronchial mast cells 
 
Examination of eosinophil count 
Blood sampling was performed to the anesthetized mice 
by an intraperitoneal injection of ketamine 200 μg/g. The 
blood collection location was in the retro-orbital 
sinus/eye of mice using a hematocrit capillary pipette. 
The application could be made by inserting the pipette at 
an angle of 45°. This method could produce large 
volumes of blood, and samples could be obtained in both 
eyes alternately, accommodated in the EDTA blood 
tube20. The examination of the blood eosinophils count 
was the eosinophils cell count x 109/L of blood plasma, 
calculated by an automated hematology analyzer. This 
variable size scale was a ratio. Data analysis was 
performed using one-way ANOVA and analyzed by 
post hoc test to determine the difference between the two 
treatment groups. Data were presented as average ± SD. 
Significance was defined at the p <0.05 level. 
Examination of bronchiolar mast cells 
Mast cell examination was carried out by histopathology 
of the mice's lungs with Toluidine blue staining and 
observed with a 400x magnification software microscope 
Image OptiLab Pro 6.121. This variable size scale was a 
ratio. Data analysis was performed using one-way 
ANOVA and then analyzed by post hoc test to determine 
the difference between the two treatment groups. Data 
were presented as average ± SD. Significance was 
defined at the p <0.05 level. 
Ethical considerations 
This research was conducted after obtaining approval 
from the health research biotech commission of the 
Faculty of Medicine, Universitas Islam Sultan Agung 
Semarang with Ethical Clearance No. 
110/IV/2020/Bioethical Commission. 
 
RESULTS AND DISCUSSION 
Normality and homogeneity analysis of the eosinophil count 
and mast cells 
The data normality test for the eosinophil count was 
performed with Shapiro-Wilk, with a p-value >0.05, 
indicating that the data were normally distributed as 
presented in Table I. As for the homogeneity of the data, 
the post hoc test results were obtained with a p-value 
>0.05, indicating that the data obtained for the eosinophil 
count and mast cells were homogeneous, as shown in 
Table II. 
Table I. Normality of data with Shapiro-Wilk test 
Groups 
Variable 
Eosinophil count (cell count x 109/L) Mast cells 
K1 0.777 0.119 
K2 0.429 0.325 
K3 0.697 0.119 
K4 0.427 0.314 
 
Table II. Data homogeneity by post hoc test 
Parameter 
Variable 
Eosinophil count Mast cells 
p-value 0.117 0.509 
 
Examination of eosinophil count 
The statistical analysis of the test results for the average, 
SD, F value, and p-value of the eosinophil count in all 
groups were presented in Table III. The K2 had the 
highest average value of all other groups. This finding 
indicates that the high average value of eosinophils in the 
K2 could be reduced by administering dexamethasone or 
M. oleifera leaves extract. The average difference between 
the two groups analyzed by post hoc test showed that the 
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109/L, and the K3 was 0.4±0.11 x 109/L, with a p-value of 
0.002 indicate that there was a significant difference 
between K2 and K3. The average difference in the K3 was 
0.4±0.11 x 109/L, and the K4 was 0.48±0.15 x 109/L, with 
a p-value of 0.503, suggesting no statistically significant 
difference between the K3 and K4 groups in reducing the 
eosinophil count. The analysis results of the average 
difference above resulted in an F value of 6.773 and a p-
value of 0.001, suggesting that the eosinophil count was 
significantly different between each study group. 
Eosinophils are promoters of type-2 inflammatory 
environment, which contribute to airway renovation in 
asthma, wherein eosinophils can increase airway 
hyperresponsiveness (AHR) and mucus 
hypersecretion22,23. Moringa oleifera seed oil is proven to 
contain flavonoid compounds that have biological 
activity as anti-asthma by reducing the thickness of the 
bronchial epithelium of asthmatic mice24. The subchronic 
toxicity effect of M. oleifera leaves extract based on liver 
histopathology shows mild reversible damage, and 
kidney histopathology shows that the renal filtration 
function of all treatment groups is still expected25. 
Moringa oleifera leaves contain phenolic compounds that 
contribute to higher antioxidant activity. They can be 
used as a potential source of natural antioxidants in 
pharmaceuticals to improve the function of the 
endogenous antioxidant system and help reduce free 
radical levels in the body26. Eosinophils contribute to 
asthma severity and may persist despite guideline-based 
treatment27. The characteristic picture of inflammation is 
characterized by an increase in the number of activated 
eosinophils causing damage to the airway epithelium28. 
Table III. Average, SD, F value, and p-value of eosinophils 
count 
Eosinophil count 
(cells x 109) 
Group 
K1 K2 K3 K4 
Average 0.38 0.9 0.4 0.48 
SD 0.14 0.3 0.11 0.15 
F value 6.773 
p-value 0.001 
 
Examination of bronchiolar mast cells 
The test results for the average, SD, F value, and p-value 
of the mast cells in groups K1, K2, K3, and K4 were 
presented in Table IV. The analysis of the average 
difference above resulted in an F value of 10.062 and a p-
value of 0.001, which means that the number of mast cells 
was significantly different between each study group. 
The K3 had the highest average number of stable mast 
cells than the K2 and K4. 
The average difference between the two groups analyzed 
by post hoc test showed that the average number of mast 
cells that were stable between the K2 was 2 ± 0.71 and the 
K3 was 4 ± 1, with a p-value of 0.003, indicates that there 
was a significant difference between the K2 and K3 
groups. It could be assumed that dexamethasone could 
stabilize mast cells. The average difference between the 
K3 was 4 ± 1, while the K4 was 3.2 ± 0.84, with a p-value 
of 0.176, which means that statistically, there was no 
significant difference between the K3 and K4 groups in 
stabilizing mast cells. 
Table IV. Average, SD, F value, and p-value of mast cells 
Mast cells 
Group 
K1 K2 K3 K4 
Average 5 2 4 3.2 
SD 1 0.71 1 0.84 
F value 10.062 
p-value 0.001 
 
The analysis of the number of stable bronchial mast cells 
in all groups was carried out by taking pulmonary 
organs. The histopathological test was carried out with 
Toluidine Blue staining, observed microscopically with a 
magnification of 400x. The histopathological picture of 
stabilizer mast cells was presented in Figure 2. In the 
lungs of patients with allergic asthma, mast cells 
accumulate in smooth muscle, bronchial epithelium, and 
alveolar parenchyma. This unique location of pulmonary 
mast cells can be replicated using a mouse model of 
allergic asthma29. Mast cells migrate to inflamed tissue 
and release pro-inflammatory mediators by 
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degranulation upon activation of cell surface receptors 
such as high-affinity IgE receptor (FcεRI), prostaglandin 
E2 receptor (PGE2), or receptors for stem cell factor in 
human and mouse mast cells30. 
 
Figure 2. Comparison of stable mast cells in the standard 
control group (K1), negative control group (K2), positive 
control group (K3), and Moringa oleifera leaves extract group 
(K4), with toluidine blue staining and 400x magnification. Red 
arrows indicate stable mast cells 
 
This study shows that M. oleifera leaves could reduce the 
eosinophil count and stabilize mast cells; in line with the 
research of Suresh et al.31, which reported that the 
methanol extract of M. oleifera leaves given to guinea pigs 
shows anti-plasma activity such as blocking the release of 
inflammatory mediators to local lung tissue and 
bronchospasm, mast cell degranulation, immune 
reactions, and anaphylactic reactions. This was found to 
inhibit the inflammatory mediator, histamine. Moringa 
oleifera extract can inhibit the release of β-hexosaminidase, 
histamine, and tumor necrosis factor (TNF)-α more 
actively than ketotifen fumarate. Moringa oleifera leaves 
has mast cell stabilizing activity and its potential to inhibit 
the final phase of the allergic response32. 
 
CONCLUSION 
Moringa oleifera Lam. leaves extract has been shown to 
reduce the eosinophil count and can stabilize the number 
of mast cells in asthmatic mice. There was no statistically 
significant difference between M. oleifera leaves extract. 
Compared with positive controls given dexamethasone 
in reducing the eosinophil count, the p-value was 0.503, 
and there was no statistically significant difference 
between M. oleifera leaves extract. While compared with 
positive controls (dexamethasone) to stabilize mast cells, 
the p-value was 0.176. 
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